pISSN 1976-2283
eISSN 2005-1212

Download original image
Fig. 2. Changes in apolipoprotein (apo) A-I (A), apo A-II (B), apo B (C), apo C-II (D), apo C-III (E), and apo E (F) levels from week 0 to week 4 during combination therapy with daclatasvir (DCV) and asunaprevir (ASV) in 44 patients. *p<0.05, p<0.01, p<0.001, §p<0.0001, and determined using Wilcoxon’s paired sign-rank test.
Gut and Liver 2018;12:201~207 https://doi.org/10.5009/gnl17179
© Gut and Liver